Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-01
2005-03-01
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S408000, C514S410000, C514S411000, C514S359000, C548S400000, C548S416000, C548S430000, C548S435000
Reexamination Certificate
active
06861441
ABSTRACT:
The present invention relates to the use of an EP4 receptor ligand in the manufacture of a medicament for use in the treatment of neuropathic pain, colon cancer, migraine, and for increasing the latency of HIV infection.
REFERENCES:
patent: 4327092 (1982-04-01), Collington et al.
patent: 5834463 (1998-11-01), Ohkawa et al.
patent: 0 501 579 (1992-09-01), None
patent: 0 520 573 (1992-12-01), None
patent: 2 330 307 (1999-04-01), None
patent: 23302307 (1999-04-01), None
Katzung, Basic and Clinical Pharmacology, 1995, p. 536-537.*
Takakazu, Oka., et al. “Biphasic modulation in the trigeminal nociceptive neuronal responses by the intracerebroventricular prostaglandin E2 may be mediated through different ep receptors subtypes in rates.” Elsevier Science Brain Research 771 (1997) pp. 278-284.
Fedyk, Eric R., et al. “A molecular analysis of PGE receptor (EP) expression on normal and transformed B Lymphocytes: comexpression of EP1, EP2, EP3βand EP4.” Molecular Immunology vol. 33, No. 1 pp. 33-45 1996 Elsevier Science.
Zeng, Li, et al. “Selective Regulation of RNK-16 cell Matrix Metalloproteinases by the Ep4subtype of prostaglandin E2receptor.” American Chemical Society, Biochemistry 1996 vol 35 pp. 7159-7164.
Coleman, R.A., et al. “A Novel inhibitory prostanoid receptor in piglet saphenous vein.” Butterworth-Heinemann—Prostaglandins 1994 vol 47 pp. 151-168.
Mori, K., et al. “Gene Expression of the human prostaglandin E receptor EP4subtype: differential regulation in monocytoid and lymphoid lineage cells by phorbol ester.” J. Mol Med 1996, vol. 74 pp. 333-336.
Ono, K., et al “Important role of EP4a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2” Jm of Endocrinology 1998, 158., pp. R1-R5.
Fedyk, R., Eric., et al “Prostaglandin E2receptors of the EP2and EP4subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells.” Proc Natl acad Sci USA vol. 93 pp. 10978-10983 Oct. 1996 Immunology.
Arakawa, T., et al., “Prostanoid receptors of Murine NIH 3T3 and RAW 264.7 Cells.” The American Soc of Biochemistry & Molecular biology Inc vol. 271 No. 47 Issue Nov. 22, 1996, pp. 29569-29575.
Mori, K., et al. “Gene expression of the human prostaglandin E receptor EP4subtype: differential regulation in monocytoid and lymphoid lineage cells by phorbol ester.” J. Mol Med 1996 74: pp. 333-336.
Sato, T., et al. “Prostaglandin E2mediates parathyroid hormone induced osteoclast formation by cyclic AMP indepnedent Mechanism.” Eicosanoids and other Bioactive Lipids in cancer inflammation & Radiation Injury 3, edited by Honn et al Plenum Press New York 1997 pp. 383-386 No. 57.
Minami, T., et al., “Characterization of EP-receptor subtypes involved in allodynia & heperalgesia induced by intrathecal administration of prostaglandin E2to mice.” Br J Pharmacol (1994) 112, pp. 735-740.
Minami, T. et al. “Blockade by ONO-NT-012 a unique prostanoid analogue of prostaglandin E2-induced allodynia in conscious mice.” Br. Jml of Pharmacology 1995 115, pp. 73-76.
Nishigaki, N. et al. “Two Gs-Coupled prostaglandin E receptor subytpes, EP2 and EP4 differ in desenitization and sensitivity to the metabolic inactivation of the agonist.” The Amer Soc for Pharma & Exper Thera. Molecular Pharmacology 50: pp. 1031-1037 (1996).
Marshall, F., et al. “Characterization of [H]-Prostaglandin E2Bind to Prostaglandin EP4Receptors Expressed with Semliki Forest Virus.” Bristish Journal of Pharmacology, 121:1673-1678 (1997).
Coleman, R., et al. “EP4-Receptors and Cyclic AMP in Pig Venous Smooth Muscle: Evidence with Agonists and the EP4-Antagonist, AH22921.” Advances in Prostaglandin, Thromboxane, and Luekotriene Research. 23:241-246 (1995).
Bamford Mark
Clayton Nicholas Maughan
Coles Richard John
Collins Susanne Denise
Doughty Jennifer M
Morgan Lorie Ann
SmithKline Beecham Corporation
Travers Russell
LandOfFree
Use of EP4 receptor ligands in the treatment of neuropathic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of EP4 receptor ligands in the treatment of neuropathic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of EP4 receptor ligands in the treatment of neuropathic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3418086